Background and objectives Obstructive nephropathy is a leading cause of CKD in children. The assessment of severity of renal impairment and the prediction of which children will progress to renal failure are, however, challenging.
Introduction
Posterior urethral valves (PUVs) are the most common cause of lower urinary tract obstruction in males. The estimated incidence of PUV is 1:5000-1:8000 of live male births (1) . The associated obstructive nephropathy and renal dysplasia are the leading cause of ESRD in surviving children (2) . Approximately 20%-30% of affected children progress to ESRD in the first decade of life, and the majority progress to CKD (3) (4) (5) .
Most cases of PUV are diagnosed by antenatal ultrasonographic findings and by postnatal confirmation by voiding cystourethrography or during cystoscopy (6) . The assessment of the severity of kidney injury is more difficult. No available tests can predict which patients will progress to ESRD. However, the severity of functional renal impairment is directly related to structural damage of the developing kidneys. In our previous studies of congenital urinary tract obstruction in the human and monkey fetus, we observed pronounced injury, characterized by a paucity of collecting ducts, tubular dilatation and atrophy, and interstitial fibrosis deep into the medulla (7) (8) (9) . To assess the extent of these injuries in humans, one would have to perform a kidney biopsy to obtain tissue for analysis. Given the inherent risks of this procedure in the fetus and younger child, surrogate markers of structural changes of obstructive nephropathy that can be measured in urine would be useful.
We have previously identified candidate proteins that are differentially expressed in the tissue of obstructed fetal kidneys compared with control kidneys (8, 9) . These included changes in scaffolding transmembrane epithelial proteins involved in cellcell adhesion, with decreases in and alteration of the distribution of E-cadherin and b-catenin, increases in N-cadherin and L1 cell adhesion molecule (L1CAM) in injured collecting-duct cells, increases in the mesenchymal proteins vimentin and a-smooth muscle actin (a-SMA) in the renal interstitium (reflecting epithelial-mesenchymal transition and myofibroblast recruitment), decreases in proteins expressed specifically by differentiated principal and intercalated cells of the collecting duct (including aquaporin-2 [AQP2] and vacuolar-type H + -adenosine triphosphatase, respectively), decreases in expression of the flowsensing protein transient receptor potential cation channel subfamily V member 4 (TRPV4) in the collecting duct, and increases in cytokines involved in fibrosis (in particular TGFb in the tubular epithelium and surrounding renal interstitium).
The major aim of this work was to study the correlation of urinary biomarker excretion and kidney function in boys with PUV. Preliminary aims were to define the feasibility of measuring these candidate biomarkers in urine and to determine whether the excretion profile of boys with PUV differed from that of children who were normal or had minor kidney abnormalities.
Materials and Methods
The study was approved and consent was waived by the Ethics Committee of the University of British Columbia.
Identification of Case-Patients
Inclusion criteria for case-patients included boys, age 1-18 years, with the diagnosis of a PUV confirmed by ultrasonography and voiding cystourethrography. Exclusion criteria included inability to provide a urine sample, age under 1 year (to control for normal tubular maturation), requirement for dialysis, or a measured GFR (mGFR) of ,15 ml/min per 1.73 m 2 . Twenty-seven children with PUV were identified from the British Columbia Children's Hospital nephrology clinical database. Urinary studies were performed on all 27 patients. Of these 27 patients, 25 had mGFRs. Estimated GFR (eGFR) was also calculated in these case-patients using the revised bedside Schwartz equation (10, 11) .
Identification of Controls
Inclusion criteria for controls included boys and girls, age 1-18 years, who were attending the outpatient general pediatric nephrology clinic at British Columbia Children's Hospital. Exclusion criteria included inability to provide a urine sample; age under 1 year of age; or an underlying diagnosis of nephrotic syndrome, primary tubular disorder, or significant hydronephrosis, which could potentially confound the interpretation of the protein studies.
Twenty control patients were enrolled and are called the "total control" group. Among these 20 patients, 2 had mild hydronephrosis (with no evidence of parenchymal damage), 2 had well controlled hypertension (1 with essential hypertension who was receiving a calcium-channel blocker, and the other with white coat hypertension who was not receiving treatment), 7 had a congenital anomaly of the kidney (2 with solitary kidneys, 4 with unilateral small kidneys, and 1 with a horseshoe kidney), and 3 had dysfunctional voiding. These 14 patients were called "non-normal" controls. The remaining 6 patients in the total control group were entirely normal, with no evidence of a kidney problem; these patients were called the "normal" controls. There was no formal prospective evaluation of kidney function in the control group; however, we identified previous serum creatinine measurements performed in these children as part of routine evaluations for other reasons. Of the 20 children, 15 had had previous serum creatinine measurements, which were all within the normal range for age, and normal eGFR (.90 ml/min per 1.73 m 2 ) when calculated using the revised bedside Schwartz equation (10, 11) .
Collection and Processing of Urine Samples
Urine samples were collected during regular clinic visits. Protease inhibitors (protease inhibitor cocktail P2714; Sigma-Aldrich, Oakville, Ontario, Canada) were added immediately to prevent degradation of urinary proteins. All samples were subsequently frozen at 220°C. Before analyses, thawed urine samples were centrifuged for 10 minutes at 300 g and for 20 minutes at 10,000 g at 4°C to remove cellular debris. For enrichment of urinary proteins, 4 ml of urine supernatant was spun in an Amicon Ultra-4 concentrator (Millipore, Billerica, MA) at 4000 g for 20 minutes to reduce volumes to about 100 ml. This fraction was designated "whole urine" for this study. Urine exosomes were then collected by centrifugation of the supernatant at 200,000 g for 1 hour at 4°C using a Beckman SW 40 rotor (Beckman Instruments, Fullerton, CA) and then resuspended in PBS with protease inhibitors. Urinary proteins and exosome-associated protein concentrations were measured by NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Middletown, VA) at 280 nm. Total protein and creatinine were measured in unconcentrated urine using UPRO and CREA (isotope dilution mass spectrometry) reagent slide methods on the VITROS 5.1 FS analyzer (Ortho Clinical Diagnostics, Rochester, NY). Urine protein measurement is a dye-binding method (pyrocatechol-violet molybdate complex), and urine creatinine is measured by an enzymatic method (creatinine amidohydrolase), with calibration traceable to a gas chromatography-isotope dilution mass spectrometry reference method. Protein in the urine was normalized to creatinine concentration and expressed as the urinary protein-to-creatinine ratio.
Immunoblotting Whole-urine and urine exosome samples were solubilized in 53 SDS-sample buffer, and equal amounts of urine and urinary exosome proteins were separated by SDS-PAGE. After fractionation by SDS-PAGE, proteins were transferred onto nitrocellulose membrane and were probed with the appropriate primary antibodies against E-cadherin (BD Transduction Laboratories, San Diego, CA); b-catenin (Cell Signaling Technology, Inc., Danvers, MA); vimentin, a-SMA, AQP2, and L1CAM (SigmaAldrich); and N-cadherin, TGFb1, vacuolar-type H + -adenosine triphosphatase, and TRPV4 (Santa Cruz Biotechnology, Santa Cruz, CA). This was followed by incubation with the appropriate antirabbit and antimouse IgG horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). Detection was carried out with enhanced chemiluminescence (Sigma-Aldrich). Densitometry of the blots was performed with ImageJ software (National Institutes of Health, Bethesda, MD), and the concentration of the biomarker protein was then expressed in arbitrary units.
Determination of Measured GFR
GFR was measured by a two-point single injection of 99m Tc-diethylenetriaminepentaacetic acid with correction for the early exponential phase using the Bröchner-Mortensen equation (12) . CKD was classified into CKD stage 1 (GFR $ 90 ml/min per 1.73 m 2 ), stage 2 (GFR, 60-89 ml/min per 1.73 m 2 ), stage 3 (GFR, 30-59 ml/min per 1.73 m 2 ), and stage 4 (GFR, 15-29 ml/min per 1.73 m 2 ) (13).
Statistical Analyses
Continuous demographic data and urinary and exosome biomarker values for the different groups were expressed as medians and range. We log transformed the data, then performed two-sided t tests for significance. Statistically significant findings were defined as P,0.05.
Pearson correlation was performed to test for correlations between individual urinary biomarker proteins, urinary protein-to-creatinine ratio, and GFR. Proteins identified as clinically or statistically significant were then studied in multivariate analyses to explore the relationship of these proteins to mGFR. Linear regression was performed to explore the relationship of these individual proteins with mGFR as the dependent variable. Logistic regression determined the relationship of the variables with mGFR , 60 ml/min per 1.73 m 2 (CKD stages 3 and 4).
In box plot graphs, boxes represent interquartile range for which the top, middle, and bottom lines are 75th percentile, median, and 25th percentile, respectively. Top and bottom lines extend to the furthest data point within 1.5 times the interquartile range. Open circle data points represent outlying values.
Receiver-operating characteristic (ROC) curves were generated to test the ability of each candidate biomarker to predict a low GFR. Sensitivities and specificities were calculated for urinary protein-to-creatinine ratio and other individual biomarker proteins at various cutoff values. All statistical analyses were performed using SPSS software, version 18.0 (SPSS Inc., Chicago, IL). Regression analyses were used to predict low GFR. We included four variables in the models: whole-urine TGFb, whole-urine L1CAM, exosome TGFb, and urinary proteinto-creatinine ratio. These variables were chosen on the basis of the strength of their individual association with mGFR and their performance by ROC curve analysis. Skewed data were log transformed before analysis.
Results
We compared our 27 prevalent case-patients with PUV with the total, normal, and non-normal control groups (Table 1) . Age did not significantly differ among the groups. Urinary protein-to-creatinine ratios in the normal, non-normal, and total control groups were similar and were significantly lower than in the case-patients (Tables  1 and 2 ). All 27 case-patients were male; in the total control group, 13 patients were female and 7 were male. Among the controls, boys and girls were similar in age and had similar excretion of biomarkers. Whole-urine aquaporin-2 (AQP2) was decreased (P,0.01) and TGFb was increased (P,0.05) in case-patients with posterior urethral valves (PUVs) compared with values in both normal and control groups, whereas excretion of L1 cell adhesion molecule (L1CAM) was increased in case-patients compared with excretion in the normal group (P,0.05). (B) Exosome E-cadherin (P,0.01) and N-cadherin (P,0.01) were decreased and TGFb (P,0.05) and L1CAM (P,0.01) were increased in case-patients with PUV compared with values in both normal and control groups. Dots are individual data points, horizontal bars represent the median values, and all data are plotted on a log-transformed y-axis. AU, arbitrary unit.
Profiles of excretion of whole-urine and exosome biomarker proteins were similar in the normal control and total control groups. For whole-urine biomarker proteins, the case-patients excreted significantly less AQP2 (P,0.001) and significantly more TGFb (P,0.05) than both control groups and significantly more L1CAM than normal controls (P,0.05) ( Table 2 and Figure 1A ). For exosome biomarker protein excretion, the casepatients excreted significantly less E-cadherin (P,0.01) and N-cadherin (P,0.01) and significantly more TGFb (P,0.05) and L1CAM (P,0.01) than both the normal and non-normal control groups (Table 3 and Figure 1B ). We could not detect E-cadherin and b-catenin in wholeurine samples or vimentin or a-SMA in either protein fraction.
In addition to more proteinuria in case-patients than controls, urinary protein-to-creatinine ratio in the casepatients increased proportionately to the decrease in renal function: from 19.2 (CKD stage 1) to 33.2 (CKD stage 2) to 53.8 (CKD stage 3) to 136.6 g/mol (CKD stage 4) (Figure 2 ). Whole-urine TGFb and L1CAM also increased with increasing CKD stage. Similarly, urinary proteinto-creatinine ratio and whole-urine TGFb correlated inversely with measured GFR (r=20.44 and 20.53, respectively); in contrast, as would be expected, eGFR correlated significantly with measured GFR (r=0.6) ( Table 4) .
There were no significant correlations between age and urinary protein-to-creatinine ratio (Table 4) or between age and any of the urinary biomarkers (Tables 4 and 5 ). There was also no relationship between age and mGFR in our case-patients.
ROC curve analyses demonstrated that whole-urine TGFb, L1CAM, urinary protein-to-creatinine ratio, exosome TGFb, and eGFR were the best tests of low GFR, with AUCs of 0.788, 0.795, 0.814, 0.654, and 0.976, respectively (Tables 6 and 7) .
Using linear regression, we found urinary protein-tocreatinine ratio, whole-urine TGFb, whole-urine L1CAM, and exosome TGFB correlated with mGFR in our casepatients (Table 8 ). According to logistic regression, none of the markers were associated with a low GFR.
Discussion
In this study, we have demonstrated that proteins that are differentially expressed in kidneys in models of obstructive nephropathy can be measured in whole urine and in urine exosomes. In recent years, urinary proteomicsbased approaches have emerged as tools for earlier detection of kidney disease, improved assessment of the severity of disease, or more precise monitoring of response to therapy (15) . Urine exosomes are particularly well suited for the study of relevant biomarkers. They contain cell membrane and cytosolic proteins that are specific for each type of epithelial cell facing the urinary space, and they reflect the physiologic or pathophysiologic state of their cells of origin (16, 17) .
The candidate biomarker proteins in this study were chosen with a biologic rationale based on our previous description of tubulo-interstitial disease in fetal animal and human studies (8, 9) . In that regard we demonstrated altered excretion of AQP2 and TGFb in whole urine and of E-cadherin, TGFb, N-cadherin, and L1CAM in urinary exosomes in our case-patients with obstructive nephropathy due to PUV compared with controls. Whereas levels of urinary TGFb and L1CAM increased with increasing CKD stage in our case-patients, TGFb levels showed the strongest correlation with mGFR. TGFb, not surprisingly, was one of the most informative proteins excreted in urine and associated with exosomes. It is a multifunctional protein that controls proliferation, differentiation, and many other functions of the cell and plays an important role in the development of tissue fibrosis (18, 19) . TGFb is a useful noninvasive diagnostic biomarker of upper and lower urinary tract obstruction (20) (21) (22) . The increased levels of urinary TGFb seen in our study probably reflect the extent of fibrosis in the kidneys of patients with PUV. Furthermore, increasing levels of TGFb in whole urine of our case-patients were associated with a decrease in mGFR, the only protein studied that demonstrated this significant relationship.
Whole-urine L1CAM excretion was increased in our case-patients and correlated with GFR. This may be explained by the fact that L1CAM is a membrane glycoprotein normally expressed at the basolateral membrane of the collecting-duct epithelial cell, which with injury is translocated to the apical membrane (23,24). We studied other potentially important biomarkers, including AQP2, a water channel (25) ; E-cadherin, a cell adhesion molecule (8, 9, 26, 27) ; and N-cadherin, another member of the cadherin family (9, 28, 29) . Although the excretion of these candidate proteins was altered in our casepatients, they did not correlate with renal function or with a reduced GFR.
Proteinuria has been described in children with PUV, but its relationship to long-term kidney outcome is unclear (30) . In our case-patients, we demonstrated a correlation between urinary protein-to-creatinine ratio and mGFR: as proteinuria increased, GFR decreased. In addition, as a biomarker of low GFR, the urinary protein-to-creatinine ratio performed best, as demonstrated by ROC curve analysis. Although proteinuria has been shown to predict renal failure in select groups of adult patients, its ability to aid in prognosticating renal outcome and CKD progression in adults with glomerular disease and in children in general is limited (31) . Therefore, other biomarkers either alone or in combination will be needed. We also studied the performance of eGFR as a biomarker of low GFR in our case-patients. Its AUC was excellent, with high specificity, but at lower GFRs (,40 ml/min per 1.73 m 2 ) the eGFR had sensitivities of 0.50 or less (Table 6 ). In other words, the eGFR had a high false-negative rate and overestimated the mGFR. It is not known whether eGFR is a valid measure or reflection of kidney injury, and it is unclear whether it can predict, alone or in combination with other biomarkers, the progression of disease or long-term outcome in PUV.
An important limitation of this study is its small sample size; we therefore may have missed important associations of candidate proteins with changes in GFR. In addition, future prospective studies with more patients are required to test the ability of these select biomarkers to predict progression and long-term outcomes in PUV. This is also a cross-sectional study, whereby only associations of the biomarkers with GFR could be drawn, emphasizing the need for larger prospective studies. Finally, future studies will be needed to measure these proteins in patients who have other significant kidney diseases, in particular those with CKD and low GFR, to determine whether these candidate biomarkers are specific to PUV.
In conclusion, we have identified and measured candidate biomarkers in the urine of patients with PUV; we have demonstrated that these children have significant differences in the excretion of many of these proteins compared with children from the clinic who are normal or have minor kidney abnormalities; and we have identified urinary protein-to-creatinine ratio, whole-urine TGFb, and L1CAM as having the best correlation with GFR and the best performance as biomarkers.
